Advertisement

Apolipoprotein E gene mutations in subjects with mixed hyperlipidemia and a clinical diagnosis of familial combined hyperlipidemia

      Abstract

      Objective

      Rare mutations in the APOE gene, undetectable with the usual genotyping technique, are responsible for dominant familial dysbetalipoproteinemia (FD) and therefore could be easily misclassified as familial combined hyperlipidemia (FCHL). We aimed to identify APOE mutations associated with dominant combined hyperlipoproteinemia and to establish their frequency in subjects with a clinical diagnosis of FCHL.

      Methods and results

      In 279 unrelated subjects with FCHL in whom a functional LDLR mutation was excluded, sequencing of the entire APOE gene detected 9 carriers of a rare mutation: 5 subjects (1.8%) with the R136S mutation (arginine at residue 136 changed to serine) and 4 subjects (1.4%) with the p.Leu149del mutation, a 3-bp inframe deletion that results in the loss of leucine at position 149. Both genetic defects were detected with similar frequency (2.5% and 1.3%, respectively) in an independent group of 160 FCHL subjects from other locations in Spain. Family studies demonstrated cosegregation of these APOE mutations with hyperlipoproteinemia. R136S carriers showed dysbetalipoproteinemia, while the lipid phenotype of p.Leu149del carriers was IIa or IIb.

      Conclusions

      Rare APOE mutations are responsible for approximately 3.5% of FCHL cases in our population. APOE R136S and p.Leu149del induce autosomal dominant FD and a phenotype indistinguishable from FCHL, respectively.

      Highlights

      • Rare APOE mutations are responsible for approximately 3.5% of FCHL cases in our population.
      • APOE R136S mutation induces autosomal dominant familial dysbetalipoproteinemia.
      • APOE p.Leu149del induces a phenotype indistinguishable from familial combined hyperlipidemia.

      Abbreviations:

      FH (familial hypercholesterolemia), FD (familial dysbetalipoproteinemia), FCHL (familial combined hyperlipidemia), CVD (cardiovascular disease), Apo (apolipoprotein), LDL (low-density lipoprotein), VLDL (very low-density lipoprotein), IDL (intermediate-density lipoprotein), HDL (high-density lipoprotein), IR (interquartile ranges)

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lee J.C.
        • Lusis A.J.
        • Pajukanta P.
        Familial combined hyperlipidemia: upstream transcription factor 1 and beyond.
        Curr Opin Lipidol. 2006; 17: 101-109
        • Genest Jr., J.J.
        • Martin-Munley S.S.
        • McNamara J.R.
        • et al.
        Familial lipoprotein disorders in patients with premature coronary artery disease.
        Circulation. 1992; 85: 2025-2033
        • Wiesbauer F.
        • Blessberger H.
        • Azar D.
        • et al.
        Familial-combined hyperlipidaemia in very young myocardial infarction survivors (<40 years of age).
        Eur Heart J. 2009; 30: 1073-1079
        • Goldstein J.L.
        • Schrott H.G.
        • Hazzard W.R.
        • Bierman E.L.
        • Motulsky A.G.
        Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia.
        J Clin Invest. 1973; 52: 1544-1568
        • Horswell S.D.
        • Ringham H.E.
        • Shoulders C.C.
        New technologies for delineating and characterizing the lipid exome: prospects for understanding familial combined hyperlipidemia.
        J Lipid Res. 2009; 50: S370-S375
        • Hopkins P.N.
        • Heiss G.
        • Ellison R.C.
        • et al.
        Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case-control comparison from the National Heart, Lung, and Blood Institute family heart study.
        Circulation. 2003; 108: 519-523
        • Civeira F.
        • Jarauta E.
        • Cenarro A.
        • et al.
        Frequency of low-density lipoprotein receptor gene mutations in patients with a clinical diagnosis of familial combined hyperlipidemia in a clinical setting.
        J Am Coll Cardiol. 2008; 52: 1546-1553
        • Mahley R.W.
        • Rall Jr., S.C.
        Type III hiperlipoproteinemia (Dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism.
        in: Scriver C.R. Beaudet A.L. Valle D. Sly W.S. The metabolic and molecular bases of inherited disease. 8th ed. McGrawn Hill, New York2001: 2835-2862
        • Ayyobi A.F.
        • McGladdery S.H.
        • McNeely M.J.
        • Austin M.A.
        • Motulsky A.G.
        • Brunzell J.D.
        Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia.
        Arterioscler Thromb Vasc Biol. 2003; 23: 1289-1294
        • de Graaf J.
        • van der Vleuten G.M.
        • ter Avest E.
        • Dallinga-Thie G.M.
        • Stalenhoef A.F.
        High plasma level of remnant-like particles cholesterol in familial combined hyperlipidemia.
        J Clin Endocrinol Metab. 2007; 92: 1269-1275
        • Gaddi A.
        • Cicero A.F.
        • Odoo F.O.
        • Poli A.A.
        • Paoletti R.
        • Atherosclerosis and Metabolic Diseases Study Group
        Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date.
        Vasc Health Risk Manage. 2007; 3: 877-886
        • Blom D.J.
        • O’Neill F.H.
        • Marais A.D.
        Screening for dysbetalipoproteinemia by plasma cholesterol and apolipoprotein B concentrations.
        Clin Chem. 2005; 51: 904-907
        • Gómez-Gerique J.A.
        • Gutiérrez-Fuentes J.A.
        • Montoya M.T.
        • et al.
        Lipid profile of the Spanish population: the DRECE (diet and risk of cardiovascular disease in Spain) study. DRECE study group.
        Med Clin (Barc). 1999; 113: 730-735
        • Jarauta E.
        • Mateo-Gallego R.
        • Gilabert R.
        • et al.
        Carotid atherosclerosis and lipoprotein particle subclasses in familial hypercholesterolaemia and familial combined hyperlipidaemia.
        Nutr Metab Cardiovasc Dis. 2010; (December, 31 [Epub ahead of print])
        • Tejedor D.
        • Castillo S.
        • Mozas P.
        • et al.
        Reliable low-density DNA array based on allele-specific probes for detection of 118 mutations causing familial hypercholesterolemia.
        Clin Chem. 2005; 51: 1137-1144
        • Houlston R.
        • Lewis B.
        • Humphries S.E.
        Polymorphisms of the apolipoprotein B and E genes and their possible roles in familial and non-familial combined hyperlipidaemia.
        Dis Markers. 1991; 9: 319-325
        • Bredie S.J.
        • Vogelaar J.M.
        • Demacker P.N.
        • Stalenhoef A.F.
        Apolipoprotein E polymorphism influences lipid phenotypic expression, but not the low density lipoprotein subfraction distribution in familial combined hyperlipidemia.
        Atherosclerosis. 1996; 126: 313-324
        • Pei W.D.
        • Zhang Y.H.
        • Sun Y.H.
        • et al.
        Apolipoprotein E polymorphism influences lipid phenotypes in Chinese families with familial combined hyperlipidemia.
        Circ J. 2006; 70: 1606-1610
        • Sing C.F.
        • Davignon J.
        Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation.
        Am J Hum Genet. 1985; 37: 268-285
        • Bennet A.M.
        • Di Angelantonio E.
        • Ye Z.
        • et al.
        Association of apolipoprotein E genotypes with lipid levels and coronary risk.
        JAMA. 2007; 298: 1300-1311
        • Huang Y.
        Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases.
        Curr Opin Lipidol. 2010; 21: 337-345
        • Davignon J.
        • Gregg R.E.
        • Sing C.F.
        Apolipoprotein E polymorphism and atherosclerosis.
        Arteriosclerosis. 1988; 8: 1-21
        • Pocovi M.
        • Cenarro A.
        • Civeira F.
        • et al.
        Incomplete dominance of type III hyperlipoproteinemia is associated with the rare apolipoprotein E2 (Arg136 → Ser) variant in multigenerational pedigree studies.
        Atherosclerosis. 1996; 122: 33-46
        • Wardell M.R.
        • Brennan S.O.
        • Janus E.D.
        • Fraser R.
        • Carrell R.W.
        Apolipoprotein E2-Christchurch (136 Arg → Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia.
        J Clin Invest. 1987; 80: 483-490
        • Nguyen T.T.
        • Kruckeberg K.E.
        • O’Brien J.F.
        • et al.
        Familial splenomegaly: macrophage hypercatabolism of lipoproteins associated with apolipoprotein E mutation [apolipoprotein E (delta149Leu)].
        J Clin Endocrinol Metab. 2000; 85: 4354-4358
        • Faivre L.
        • Saugier-Veber P.
        • Pais de Barros J.P.
        • et al.
        Variable expressivity of the clinical and biochemical phenotype associated with the apolipoprotein E p.Leu149del mutation.
        Eur J Hum Genet. 2005; 13: 1186-1191
        • Lalazar A.
        • Weisgraber K.H.
        • Rall S.C.
        • et al.
        Site-specific mutagenesis of human apolipoprotein E.
        J Biol Chem. 1988; 263: 3542-3545
        • Grundy S.M.
        • Cleeman J.I.
        • Daniels S.R.
        • et al.
        Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement.
        Circulation. 2005; 112: 2735-2752
        • Solanas-Barca M.
        • Mateo-Gallego R.
        • Calmarza P.
        • et al.
        Mutations in HFE causing hemochromatosis are associated with primary hypertriglyceridemia.
        J Clin Endocrinol Metab. 2009; 94: 4391-4397
        • Goldberg A.C.
        • Hopkins P.N.
        • Toth P.P.
        • et al.
        Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
        J Clin Lipidol. 2011; 5: 133-140